Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Neoadjuvant androgen deprivation therapy in men with high-risk localized prostate cancer

Rana R. McKay, MD, of UC San Diego Health, La Jolla, CA, discusses results of a phase II study evaluating abiraterone + prednisone + apalutamide + leuprolide (APAL) or abiraterone + prednisone + leuprolide (APL) in the neoadjuvant setting prior to radical prostatectomy for high risk, localized, prostate cancer patients (NCT02903368). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).